Navigation Links
Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
Date:8/21/2008


Satisfies initial listing requirements with NASDAQ; Stock Symbol 'OGXI'

Implements immediate restructuring program, which extends cash runway

while focusing on clinical pipeline programs

BOTHELL, WA, Aug. 21 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.) (NASDAQ: OGXI) (the "Company") announced that the Company has completed its acquisition of OncoGenex Technologies and NASDAQ has approved the commencement of trading in Company's common stock on The NASDAQ Capital Market under the stock symbol 'OGXI' effective today, August 21, 2008, when the market opens. Prior to completing the acquisition, the Company changed its name to OncoGenex Pharmaceuticals, amended its authorized share capital and effected a one-for-eighteen reverse stock split.

"Clearly the shareholders of both companies, Sonus Pharmaceuticals and OncoGenex Technologies, strongly favored this transaction and our efforts to maintain a NASDAQ listing," said Scott Cormack, President and Chief Executive Officer of OncoGenex Pharmaceuticals. "On August 19th, a very strong percentage of Sonus' shareholders voted in favor of the transaction and voted in favor of a reverse stock split. One hundred percent of OncoGenex Technologies' shareholders voted in favor of the transaction."

Additionally, as announced on August 20th, the Company has implemented cost-saving measures to preserve cash while focusing on its highest potential product development programs. The Company will reduce workforce by approximately 49%. As a result of these actions, the Company will incur approximately $1.2 million in charges in the third quarter of 2008, associated with employee severance costs. Management estimates that
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
2. Sonus Pharmaceuticals Receives Favorable NASDAQ Decision
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... Md. , April 1, 2015  VLP Therapeutics, ... company focusing on the research and development of therapeutic ... upon a novel and proprietary vaccine technology, today announced ... Institute of Tropical Medicine at Nagasaki ... collaboration will facilitate VLP,s research and development of dengue ...
(Date:4/1/2015)... , April 1, 2015  ValGenesis Inc., the ... announced today that it has completed its Service Organization ... Attest Engagements (AICPA, Professional Standards) for the period of ... 2014.  ... The SOC 2 ...
(Date:4/1/2015)... Goldman Small Cap Research, a stock market research firm ... today that it has issued a new article on ... clinical stage biotechnology company focused on developing and preparing ... research article, along with disclosures and disclaimers, or to ... .  In the article on the ...
(Date:4/1/2015)... , April 1, 2015 /PRNewswire/ - Portage Biotech ... PBT.U), is pleased to announce that Biohaven Pharmaceutical ... equity, has entered into an agreement with inVentiv ... clinical trial with their lead compound (BHV-0223). ... and development of clinical stage neuroscience compounds targeting ...
Breaking Biology Technology:VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 2VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 3ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 2ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 3Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 2Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 3Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 4Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3
... FORT LAUDERDALE, Fla., Dec. 27 Imaging,Diagnostic Systems, ... laser,optical breast cancer imaging systems, announced that Tim ... Director effective January 1, 2008., (Logo: ... IDSI Chief Executive Officer and a Director of,the ...
... SOUTHAMPTON, Pa., Dec. 27 Environmental,Tectonics Corporation,s (Amex: ... today announced the purchase of two (2) BARA-MED(R) ... ETC is,excited to work with Comprehensive Healthcare Solutions ... operating Wound Healing Institutes,throughout the United States., ...
... 26 Insmed Inc. (Nasdaq:,INSM), a developer of ... requested a hearing before a Nasdaq Listing,Qualifications Panel ... the,Company,s common stock from the Nasdaq Global Market., ... Stock Market ("Nasdaq") on,December 20, 2007 indicating that ...
Cached Biology Technology:Imaging Diagnostic Systems CEO Announces Retirement 2Imaging Diagnostic Systems CEO Announces Retirement 3Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers 2Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers 3Insmed to Appeal Delisting Notification From Nasdaq 2
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications ... a global provider of Software Defined Network Architecture (ET ... announced total revenue of approximately $20.4 million for the ... restated $19.5 million for the year ended December 31, ... 2014, the Company had completed its multi-year transition away ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... is turning yellow. Do you gun the engine and speed ... green, or do you slow down and wait your turn? ... new research from Tel Aviv University. Arnon Lotem, a behavioral ... reports in the prestigious journal Nature that people adopt risk-taking ...
... PASADENA, Calif.-- Individuals with synesthesia perceive the world in ... their senses are ,cross-activated, some synesthetes perceive numbers or ... as possessing personalities, even ,as they function normally in ... Technology have discovered a type of ,synesthesia in which ...
... of York have helped to reveal more about the way ... could help in the development of new treatments for serious ... studied the way a protein found on the surface of ... fibronectin. Their discovery is an important step in understanding how ...
Cached Biology News:Humans' response to risk can be unnecessarily dangerous, finds Tel Aviv University study 2Caltech neurobiologists discover individuals who 'hear' movement 2Caltech neurobiologists discover individuals who 'hear' movement 3
... cassette is designed to allow ampicillin selection ... gb2 driving the gene for ampicillin resistance ... Em7 promoter. It mediates higher transcription efficiency ... synthetic polyadenylation signal terminates the ampicillin expression. ...
... The PRO S-7 stirrers ... Spill-resistant housing channels fluids away ... panel features easy-to-use controls which ... 7"x7" ceramic tops feature ...
... loxP-cm-loxP cassette is designed to ... The prokaryotic promoter gb2 driving ... a slightly modified version of the ... efficiency than the generally used Tn5 ...
... This kit is designed for the ... large vector plasmids at any position (for ... included loxP-PGK-gb2-neo-loxP cassette is designed to allow ... eukaryotic cells. It combines a prokaryotic promoter ...
Biology Products: